Sanofi India Limited (IN:SANOFI)
:SANOFI
Top Page
Sanofi India Limited
(SANOFI)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹3,701.00
▼(-10.66% Downside)
Action:UpgradedDate:02/27/26
The score is driven primarily by strong financial quality (low leverage and solid cash generation), partially offset by softer fundamentals (revenue decline and margin compression). Technicals remain weak with the stock below key moving averages, while valuation is supported by the high dividend yield but tempered by a higher P/E.
Positive Factors
Conservative balance sheet
Very low leverage gives Sanofi India durable financial flexibility to fund operations, absorb shocks, and support strategic initiatives without heavy refinancing. This conservatism supports creditworthiness and long-term resilience, enabling capital allocation to growth or shareholder returns when opportunities arise.
Negative Factors
Weakening revenue trend
A multi-year choppy top-line and a 2025 revenue decline suggest slower market traction or competitive pressures. Persistent topline weakness can constrain reinvestment, limit economies of scale, and make earnings and cashflow more sensitive to cost or pricing shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage gives Sanofi India durable financial flexibility to fund operations, absorb shocks, and support strategic initiatives without heavy refinancing. This conservatism supports creditworthiness and long-term resilience, enabling capital allocation to growth or shareholder returns when opportunities arise.
Read all positive factors
Sanofi India Limited (SANOFI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹77.14B
Dividend Yield4.73%
Average Volume (3M)3.77K
Price to Earnings (P/E)38.1
Beta (1Y)0.84
Revenue Growth-19.94%
EPS Growth-22.49%
CountryIN
Employees1,225
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)26.80
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)170.03
Revenue Forecast (FY)₹19.55B
Sanofi India Limited Business Overview & Revenue Model
Company Description
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous...
How the Company Makes Money
Sanofi India makes money primarily by selling pharmaceutical and consumer healthcare products in India. Its revenue model is largely product-sales driven: it earns income from the sale of prescription medicines (through healthcare-provider prescri...
Sanofi India Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
90
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.16B | 18.37B | 20.13B | 19.96B | 27.70B | 29.57B |
| Gross Profit | 9.58B | 7.18B | 10.19B | 10.31B | 15.65B | 16.33B |
| EBITDA | 4.63B | 4.91B | 4.85B | 4.85B | 6.98B | 7.54B |
| Net Income | 3.38B | 3.27B | 4.13B | 6.03B | 6.21B | 9.44B |
Balance Sheet | ||||||
| Total Assets | 12.39B | 12.55B | 16.12B | 17.15B | 20.72B | 30.61B |
| Cash, Cash Equivalents and Short-Term Investments | 3.13B | 2.75B | 3.40B | 3.94B | 10.05B | 15.38B |
| Total Debt | 209.00M | 178.00M | 193.00M | 190.00M | 236.00M | 246.00M |
| Total Liabilities | 4.57B | 5.06B | 7.51B | 7.00B | 7.96B | 8.35B |
| Stockholders Equity | 7.82B | 7.49B | 8.61B | 10.15B | 12.76B | 22.26B |
Cash Flow | ||||||
| Free Cash Flow | 2.77B | 4.25B | 4.25B | 1.96B | 3.77B | 5.36B |
| Operating Cash Flow | 2.91B | 4.51B | 4.62B | 2.30B | 3.99B | 5.59B |
| Investing Cash Flow | -71.00M | -253.00M | -192.00M | 375.00M | 6.51B | 6.31B |
| Financing Cash Flow | -2.73B | -4.46B | -3.92B | -8.78B | -15.83B | -8.49B |
Sanofi India Limited Technical Analysis
Negative
4142.75
Price Trends
3811.32
Negative
4055.36
Negative
4657.11
Negative
Market Momentum
-182.98
Positive
28.13
Positive
28.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Negative. The current price of 4142.75 is above the 20-day moving average (MA) of 3471.49, above the 50-day MA of 3811.32, and below the 200-day MA of 4657.11, indicating a bearish trend. The MACD of -182.98 indicates Positive momentum. The RSI at 28.13 is Positive, neither overbought nor oversold. The STOCH value of 28.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SANOFI.
Sanofi India Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹77.14B | 38.14 | ― | 4.73% | -19.94% | -22.49% | |
70 Outperform | ₹1.02T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹970.23B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
67 Neutral | ₹550.59B | 41.01 | ― | 1.68% | 10.69% | 17.46% | |
63 Neutral | ₹397.54B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
53 Neutral | ₹593.88B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SANOFI
Sanofi India Limited
3,349.40
-2,616.15
-43.85%
IN:ABBOTINDIA
Abbott India Limited
25,911.00
-3,099.06
-10.68%
IN:CIPLA
Cipla Ltd
1,201.10
-217.19
-15.31%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,217.20
115.64
10.50%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,346.65
-347.24
-12.89%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,104.45
669.02
46.61%
Sanofi India Limited Corporate Events
Sanofi India Flags Transfer of Dormant Shareholdings to IEPF
Mar 14, 2026
Sanofi India Limited has notified stock exchanges that it has published newspaper advertisements alerting shareholders whose dividends have remained unclaimed for seven consecutive years or more. In line with Section 124(6) of the Companies Act, 2...
Sanofi India Publishes Transcript of Investor Call on 2025 Financial Results
Mar 5, 2026
Sanofi India Limited has notified the stock exchanges that it has made available the transcript of its investor and analyst call held on 26 February 2026, covering the financial results for the quarter and year ended 31 December 2025. The disclosu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.